KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
Fotios Loupakis, Annamaria Ruzzo, Chiara Cremolini et al. · British Journal of Cancer · 2009
BACKGROUND: KRAS codons 12 and 13 mutations predict resistance to anti-EGFR monoclonal antibodies (moAbs) in metastatic colorectal cancer. Also, BRAF V600E mutation has been associated with resistance. Additional KRAS mutations are described in CRC. METHODS: We investigated the role of KRAS codons 61 and 146 and BRAF V600E mutations in predicting resistance to cetuximab plus irinotecan in a cohort of KRAS codons 12 and 13 wild-type patients. RESULTS: Among 87 KRAS codons 12 and 13 wild-type patients, KRAS codons 61 and 146 were mutated in 7 and 1 case, respectively. None of mutated patients responded vs 22 of 68 wild type (P=0.096). Eleven patients were not evaluable. KRAS mutations were associated with shorter progression-free survival (PFS, HR: 0.46, P=0.028). None of 13 BRAF-mutated patients responded vs 24 of 74 BRAF wild type (P=0.016). BRAF mutation was associated with a trend towards shorter PFS (HR: 0.59, P=0.073). In the subgroup of BRAF wild-type patients, KRAS codons 61/146 mutations determined a lower response rate (0 vs 37%, P=0.047) and worse PFS (HR: 0.45, P=0.023). Patients bearing KRAS or BRAF mutations had poorer response rate (0 vs 37%, P=0.0005) and PFS (HR: 0.51, P=0.006) compared with KRAS and BRAF wild-type patients. CONCLUSION: Assessing KRAS codons 61/146 and BRAF V600E mutations might help optimising the selection of the candidate patients to receive anti-EGFR moAbs.
Cited by 564 works. doi:10.1038/sj.bjc.6605177 Open-access PDF
Authors
- Fotios Loupakis
- Annamaria Ruzzo
- Chiara Cremolini
- Bruno Vincenzi
- Lisa Salvatore
- Daniele Santini
- Gianluca Masi
- I. Stasi
- Emanuele Canestrari
- Eliana Rulli
- Irene Floriani
- Katia Bruna Bencardino
- Nadia Galluccio
- Vincenzo Catalano
- Giuseppe Tonini
- Mauro Magnani
- Gabriella Fontanini
- Fulvio Basolo
- Alfredo Falcone
- Francesco Graziano
References
- New Guidelines to Evaluate the Response to Treatment in Solid Tumors
- ras oncogenes in human cancer: a review.
- Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
- Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
- K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
- Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer
- Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer